Literature DB >> 2467983

Antagonist effects of nalbuphine in opioid-dependent human volunteers.

K L Preston1, G E Bigelow, I A Liebson.   

Abstract

The subjective, physiological and behavioral effects of nalbuphine, an opioid mixed agonist/antagonist analgesic, naloxone and hydromorphone were studied on adult, male, methadone-dependent volunteers living on a clinical research ward. The purpose was to assess nalbuphine's agonist properties vs. antagonist properties relative to a standard agonist (hydromorphone) and a standard antagonist (naloxone) in opioid-dependent subjects. Drug conditions included saline placebo, nalbuphine hydrochloride (0.375, 0.75, 1.5, 3 and 6 mg), naloxone hydrochloride (0.1 and 0.2 mg) and hydromorphone hydrochloride (4 and 8 mg). Drug conditions, given by i.m. injection, were tested in five subjects under double-blind conditions in 2.5 hr experimental sessions. Physiologic measures were monitored continuously before and for 2 hr after drug administration: pupil diameter and subject- and observer-rated behavioral responses were measured intermittently over this same period. Hydromorphone increased ratings significantly on subjective measures typical of morphine-like effects. Naloxone precipitated opioid abstinence which was measurable on several subject- and observer-rated behavioral measures and physiological measures. Nalbuphine produced effects which were qualitatively similar to the effects of naloxone and showed no evidence of opioid agonist effects in these methadone-dependent subjects. The withdrawal syndrome precipitated by nalbuphine was indistinguishable from that produced by naloxone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467983

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Nalbuphine and slow release morphine.

Authors:  Jason Smith; Henry Guly
Journal:  BMJ       Date:  2004-06-12

2.  Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

3.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

4.  Subjective and behavioral responses to intravenous fentanyl in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; J G Zaragoza; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men.

Authors:  Nancy K Mello; Jack H Mendelson; Michelle B Sholar; Maria Jaszyna-Gasior; Nathalie Goletiani; Arthur J Siegel
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

6.  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Authors:  Lisa S Middleton; Paul A Nuzzo; Michelle R Lofwall; David E Moody; Sharon L Walsh
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

7.  Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; W Binstock; D W Coalson; T Cutter; D C Flemming; B Glosten
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers.

Authors:  Nathalie V Goletiani; Jack H Mendelson; Michelle B Sholar; Arthur J Siegel; Alicja Skupny; Nancy K Mello
Journal:  Pharmacol Biochem Behav       Date:  2007-02-20       Impact factor: 3.533

9.  Effects of buprenorphine and methadone in methadone-maintained subjects.

Authors:  S L Walsh; H L June; K J Schuh; K L Preston; G E Bigelow; M L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

10.  Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.

Authors:  Monique M Cherrier; John K Amory; Mary Ersek; Linda Risler; Danny D Shen
Journal:  J Pain       Date:  2009-09-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.